Barclays PLC Harmony Biosciences Holdings, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Barclays PLC holds 76,862 shares of HRMY stock, worth $2.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

76,862

Previous 76,862 -0.0%

Holding current value

$2.52 Million

Previous $3.07 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$30.0 - $39.95 $1.21 Million - $1.61 Million	40,416 Added 110.89%	76,862 $3.07 Million
Q2 2024 Aug 14, 2024	SELL	$28.81 - $33.01 $388,877 - $445,568	-13,498 Reduced 27.03%	36,446 $1.1 Million
Q1 2024 May 15, 2024	SELL	$29.93 - $35.06 $637,928 - $747,268	-21,314 Reduced 29.91%	49,944 $1.68 Million
Q4 2023 Feb 15, 2024	BUY	$19.2 - $33.78 $711,724 - $1.25 Million	37,069 Added 108.42%	71,258 $2.3 Million
Q3 2023 Nov 07, 2023	BUY	$31.89 - $39.03 $142,261 - $174,112	4,461 Added 15.01%	34,189 $1.12 Million
Q2 2023 Aug 03, 2023	BUY	$30.5 - $37.4 $22,875 - $28,050	750 Added 2.59%	29,728 $1.05 Million
Q1 2023 May 04, 2023	BUY	$30.8 - $53.92 $176,145 - $308,368	5,719 Added 24.59%	28,978 $946,000
Q4 2022 Feb 13, 2023	SELL	$45.4 - $60.91 $39,997 - $53,661	-881 Reduced 3.65%	23,259 $1.28 Million
Q3 2022 Nov 03, 2022	BUY	$42.06 - $55.45 $58,168 - $76,687	1,383 Added 6.08%	24,140 $1.07 Million
Q2 2022 Aug 12, 2022	SELL	$33.54 - $52.15 $148,313 - $230,607	-4,422 Reduced 16.27%	22,757 $1.11 Million
Q1 2022 May 16, 2022	BUY	$33.14 - $51.13 $900,712 - $1.39 Million	27,179 New	27,179 $1.32 Million

Others Institutions Holding HRMY

# of Institutions

242

Shares Held

45.2M

Call Options Held

108K

Put Options Held

49.2K

View Full List

About Harmony Biosciences Holdings, Inc.

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $1.94B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

More about HRMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account